Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...

Calquence starts working as soon as you start taking it. But it can take time to see results on laboratory or imaging tests. You’ll likely continue taking Calquence for as long as it’s ...

Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...

Positive” results from the AMPLIFY Phase III trial showed AstraZeneca’s (AZN) Calquence in combination with venetoclax demonstrated a ...

Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...

Calquence (acalabrutinib) is a brand-name oral tablet that’s prescribed for certain types of cancer in adults. As with other drugs, Calquence can cause side effects, such as low levels of blood ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

Calquence (acalabrutinib) is a prescription drug that’s used to treat certain types of leukemia and lymphoma, which are blood cancers. Calquence can cause side effects that range from mild to ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...